Fair enough, I do also feel their salaries are too overly remunerated.
But same token the key insiders have also purchased plenty of shares out of their paid salary as well, might not be as bad as it seem.
I am also in for at least few quarters to see if they can receive the FDA approval as well as achieving revenues from their product commercialisation, as promised by their team to be done in Q1 2024
AYA Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
